Market Closed -
Nasdaq
04:30:01 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
0.47
USD
|
-2.08%
|
|
-4.14%
|
-10.03%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
40.57
|
27.17
|
19.11
|
6.162
|
4.017
|
12.34
|
-
|
-
|
Enterprise Value (EV)
1 |
40.57
|
27.17
|
19.11
|
6.162
|
4.017
|
12.34
|
12.34
|
12.34
|
P/E ratio
|
-4.49
x
|
-2.79
x
|
-0.85
x
|
-0.18
x
|
-0.19
x
|
-141
x
|
-1.68
x
|
-1.96
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
15.1
x
|
2,264
x
|
-
|
-
|
-
|
1.01
x
|
8.23
x
|
-
|
EV / Revenue
|
15.1
x
|
2,264
x
|
-
|
-
|
-
|
1.01
x
|
8.23
x
|
-
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-1,744,603
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
101
|
138
|
316
|
1,796
|
7,689
|
26,256
|
-
|
-
|
Reference price
2 |
400.8
|
197.2
|
60.40
|
3.430
|
0.5224
|
0.4700
|
0.4700
|
0.4700
|
Announcement Date
|
3/4/20
|
3/25/21
|
4/15/22
|
3/23/23
|
3/25/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
2.686
|
0.012
|
-
|
-
|
-
|
12.17
|
1.5
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-7.109
|
-8.213
|
-16.94
|
-12.31
|
-12.59
|
-0.9213
|
-15.14
|
-18.88
|
Operating Margin
|
-264.67%
|
-68,439.67%
|
-
|
-
|
-
|
-7.57%
|
-1,009.13%
|
-
|
Earnings before Tax (EBT)
1 |
-7.001
|
-8.08
|
-16.7
|
-13.7
|
-12.42
|
-0.8947
|
-15.14
|
-18.88
|
Net income
1 |
-7.097
|
-8.092
|
-16.39
|
-13.58
|
-13.04
|
-0.8947
|
-15.14
|
-18.88
|
Net margin
|
-264.21%
|
-67,432.83%
|
-
|
-
|
-
|
-7.35%
|
-1,009.13%
|
-
|
EPS
2 |
-89.20
|
-70.80
|
-70.80
|
-18.55
|
-2.690
|
-0.003330
|
-0.2800
|
-0.2400
|
Free Cash Flow
|
-
|
-
|
-10.95
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/4/20
|
3/25/21
|
4/15/22
|
3/23/23
|
3/25/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
8
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-2.967
|
-8.649
|
-3.569
|
-2.402
|
-3.703
|
-2.635
|
-1.917
|
-2.633
|
-5.919
|
-2.119
|
5.401
|
-3.144
|
-3.212
|
-3.279
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
67.51%
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-2.967
|
-8.683
|
-3.565
|
-2.401
|
-5.119
|
-2.611
|
-1.869
|
-2.614
|
-5.763
|
-2.178
|
5.411
|
-3.134
|
-3.202
|
-3.269
|
Net income
1 |
-2.967
|
-8.378
|
-3.565
|
-2.401
|
-5.119
|
-2.498
|
-1.869
|
-2.614
|
-6.294
|
-2.269
|
5.411
|
-3.134
|
-3.202
|
-3.269
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
67.64%
|
-
|
-
|
-
|
EPS
2 |
-11.60
|
-31.20
|
-10.80
|
-7.200
|
-6.030
|
-1.757
|
-1.000
|
-0.7900
|
-0.8900
|
-
|
0.2750
|
-0.0800
|
-0.0800
|
-0.0850
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/15/21
|
4/15/22
|
7/8/22
|
8/12/22
|
11/9/22
|
3/23/23
|
5/9/23
|
8/8/23
|
11/9/23
|
3/25/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-11
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
0.06
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/4/20
|
3/25/21
|
4/15/22
|
3/23/23
|
3/25/24
|
-
|
-
|
-
|
Last Close Price
0.47
USD Average target price
3.667
USD Spread / Average Target +680.14% Consensus |
1st Jan change
|
Capi.
|
---|
| -10.03% | 12.34M | | -2.31% | 103B | | +0.56% | 95.28B | | +0.64% | 22.15B | | -17.37% | 21.02B | | -8.35% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|